Grifols (NASDAQ:GRFS) Lowered to “Hold” at StockNews.com

Posted by on Apr 26th, 2023

Grifols (NASDAQ:GRFS – Get Rating) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

GRFS has been the topic of several other reports. Barclays raised shares of Grifols from an “underweight” rating to an “equal weight” rating in a research note on Thursday, February 16th. Morgan Stanley raised shares of Grifols from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 12th. AlphaValue raised shares of Grifols to a “buy” rating in a research report on Monday, February 6th. Finally, Jefferies Financial Group raised shares of Grifols from a “hold” rating to a “buy” rating in a research report on Wednesday, January 18th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.52.

Grifols Stock Performance

Shares of GRFS opened at $7.21 on Wednesday. The company has a 50-day simple moving average of $7.90 and a 200-day simple moving average of $7.99. Grifols has a 52 week low of $5.71 and a 52 week high of $13.34. The company has a quick ratio of 0.74, a current ratio of 2.38 and a debt-to-equity ratio of 1.18.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of GRFS. Flat Footed LLC grew its position in shares of Grifols by 497.5% in the 3rd quarter. Flat Footed LLC now owns 5,600,181 shares of the biotechnology company’s stock valued at $34,497,000 after acquiring an additional 4,662,971 shares during the period. First Trust Advisors LP raised its position in shares of Grifols by 65.6% in the 4th quarter. First Trust Advisors LP now owns 7,242,059 shares of the biotechnology company’s stock valued at $61,558,000 after buying an additional 2,869,022 shares in the last quarter. Capital World Investors raised its position in shares of Grifols by 15.2% in the 1st quarter. Capital World Investors now owns 17,172,143 shares of the biotechnology company’s stock valued at $200,571,000 after buying an additional 2,265,005 shares in the last quarter. Norges Bank bought a new stake in shares of Grifols during the 4th quarter valued at approximately $19,218,000. Finally, Point72 Asset Management L.P. grew its holdings in shares of Grifols by 919.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,383,600 shares of the biotechnology company’s stock valued at $14,683,000 after purchasing an additional 2,149,771 shares during the last quarter. Institutional investors own 14.41% of the company’s stock.

Grifols Company Profile

(Get Rating)

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy.

Featured Stories

Analyst Recommendations for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.